Evidence-based treatments for the asymptomatic HIVpositive patient in general practice by Matchaba, P
The South African Department of Health
estimates the national HIV seroprevalence
to be 24.8%.1 The highest is found in
KwaZulu-Natal (KZN) at 33.5% and the
lowest in the Western Cape (WC), with a
seroprevalence of 8.6%. Although these
figures were obtained from women aged
between 15 and 49 years attending public
antenatal clinics, they may be extrapolated
to the sexually active population as a
whole. Further, the overwhelming majori-
ty of the women attending antenatal clin-
ics are healthy and therefore asympto-
matic. From this research and others2 one
can conclude that the number of asymp-
tomatic HIV-positive patients seen in a
typical general practice today is significant
and covers all age groups and races. The
challenge is to manage them using the
best available evidence.This is com-
pounded by the fact that South African
doctors practise in a resource-constrained
environment, and most doctors in general
practice today were trained when HIV was
either not present or not as common as it
is today.
The challenges are divided into two sec-
tions which are likely to represent patient
population profiles seen in general prac-
tice:
• the adult non-pregnant HIV-positive
asymptomatic patient 
• the HIV-positive pregnant asymptomatic
patient.
The following simple grading system is
used for judging and recommending what
is and what is not good research evidence
of the effect of an intervention:
• A grade: treatment evidence based on a
systematic review (SR) of randomised
controlled trials (RCTs) and/or from a
well-designed large RCT
• B grade: treatment evidence based on a
RCT that is not well designed, with
inadequate power to answer the research
question or methodologically flawed
• C grade: treatment evidence based on
observational studies (non-RCT or SR) 
• D grade: treatment evidence based on




PATIENT IN GENERAL PRACTICE
To test or not to test
The first practical problem is getting a
patient suspected from clinical history and
examination to be HIV-positive, to agree
to testing.There is no research that looks
at interventions at the general practice
level that would lead to an increase in the
number of patients volunteering for test-
ing. However trust between the patient
and the doctor, assuring confidentiality
and the patient seeing value in knowing
his/her HIV status, seems to be important.
Knowing HIV status should translate into
a decrease in the patient’s risk of falling ill
from opportunistic infections and malig-
nancies and eventually from premature
death.The risk of opportunistic infections
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treatment vital.
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increases significantly when the
CD4 count falls below 250/mm3.3
Preventing opportunistic 




There is grade-A evidence from
two SRs4,5 and several well-con-
ducted RCTs6-9 that shows that in
people who are both HIV- and
tuberculin-positive, prophylactic
anti-TB drugs significantly reduce
the risk of active TB in the short
term.There is evidence that with-
out anti-TB prophylaxis, patients
who are HIV- and tuberculin-posi-
tive have a 50% or more lifetime
risk of developing TB compared
with a 10% risk in those who are
tuberculin-negative.10 Anti-TB pro-
phylaxis in this context becomes of
tremendous value to the asympto-
matic HIV patient in general prac-
tice.The magnitude of the benefit
for patients randomised to isoni-
azid prophylactically (or in combi-
nation with pyrazinamide) versus
patients randomised to receive
placebo was a 76% decrease in TB
over 2 - 3 years (RR compared
with placebo 0.24, 95% CI 0.14 -
0.40) in the SR by Bucher et al.5
There was also a trend towards a
reduction in deaths (RR compared
with placebo 0.77, 95% CI 0.58 -
1.03). One assumes that if the
studies had a longer follow-up
period the difference in death rates
would have been significant.
Giving anti-TB prophylaxis in
tuberculin-negative patients has
been shown to be no different from
no treatment or placebo.
Which anti-TB prophylactic
regimen?
There is grade-A evidence from
the well-conducted RCT refer-
enced above, that there is no differ-
ence in the rate of  TB recurrence
or infections, between using pyrazi-
namide with rifampicin in combi-
nation versus isoniazid alone, in
HIV-positive and tuberculin skin-
positive patients.
For how long should a patient
take anti-TB prophylaxis?
The RCT evidence above com-
pared 2 - 3 months’ treatment per
year for combination treatment
(rifampicin and pyrazinamide) ver-




nia (PCP) and toxoplasmosis
beneficial?
There is grade-A evidence from
SRs11 and RCTs12,13 that trimetho-
prim/sulfamethoxazole (TMP-
SMX) —  co-trimoxazole —  is
more effective than pentamidine or
placebo at reducing the risk of
PCP or toxoplasmosis infections in
patients who are HIV-positive.
Patients given TMP-SMX
(Bactrim equivalent) had a 68%
decrease in the risk of PCP com-
pared with those given placebo
(RR 0.32, 95% CI 0.23 - 0.46)
and a 42% greater risk reduction
compared with those given
aerolised pentamidine (RR 0.58,
95% CI 0.45 - 0.75).
Which dose of TMP-SMX?
There was no significant difference
in the rate of PCP infections
between patients on high doses
(160/800 mg daily) and those on
low doses (160/800 mg 3 times
weekly or 80/400 mg daily).
Does prophylaxis with antifun-
gal drugs decrease the inci-
dence of candidiasis in the
asymptomatic HIV-positive
patient?
Grade-A evidence from a RCT14
found that women taking weekly
fluconazole had a 58% decrease in
the incidence of candidiasis com-
pared with a 44% decrease in those
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There is evidence
that without anti-TB
p r o p h y l a x i s ,
patients who are
HIV- and tuberculin-
positive have a 50%
or more lifetime risk
of developing TB
compared with a
10% risk in those
who are tuberculin-
n e g a t i v e .
In summary
• There is grade-A evidence that




should have a tuberculin skin
test and should be offered pro-
phylaxis if found to be posi-
tive.)
• There is no difference between
the short-term (2 - 3 months)
combination therapy and the
long-term (6 - 12 months) iso-
niazid therapy. These regimens
should be followed yearly if on
short course. (Advice: individu-




• There is grade-A evidence that
prophylaxis with TMP-SMX in
low doses is beneficial in
decreasing PCP and toxoplas-
mosis infections.
• Higher doses of TMP-SMX are
associated with an increase in
severe side-effects (rash, fever)
which may lead to poor com-
pliance.
taking placebo (RR 0.56, 95% CI
0.41 - 0.77). Fluconazole was
found to be more effective than
clotrimazole in decreasing the inci-
dence of invasive fungal disease
and mucocutaneous candidal
infections (11% decrease v. 4%).15
Which dose of fluconazole?
There was no difference in the rate
of invasive fungal infections
between high-dose fluconazole
(200 mg daily) and low doses (400
mg once a week).16
Does prophylaxis with 
aciclovir, valaciclovir and fam-
ciclovir decrease the risk of
cytomegalovirus (CMV),her-
pes simplex virus (HSV) and
varicella zoster virus (VZV)?
There is grade-A evidence from a
SR17 that in patients who were both
asymptomatic and had full-blown
AIDS, there was no difference in
the incidence of CMV between
those randomised to aciclovir com-
pared with those who received no
treatment or placebo. However
there was a significant decrease in
HSV and VZV (p < 0.001). One
RCT18 in patients with CD4
counts < 100 showed an increased
mortality in the valaciclovir group
(p = 0.06), but a lower rate of
CMV infection compared with
those allocated to aciclovir (12% v.
18%; p = 0.03). Another RCT
found that patients with frequent
recurrences of HSV who took fam-
ciclovir had decreased HSV infec-
tions (HSV isolated in 9/1 071
famciclovir days v. 122/1 114
placebo days; p < 0.001).19
Is there evidence for prophy-
laxis against Mycobacterium
avium complex (MAC) in the
asymptomatic HIV-positive
patient?
There are no SRs or well-conduct-
ed RCTs (grade-A evidence) that
address the question of
azithromycin and clarithromycin,
either alone or in combination, in
asymptomatic HIV-positive
patients. Two trials have been done
in patients with AIDS as the risk of
developing MAC increases with





The following questions need to be
addressed:
• What is the evidence regarding
the use of antiretrovirals (ARVs)
in preventing mother-to-child
transmission (MTCT)?
• Which regimen of ARVs should
be used and what about vitamin
A and multivitamin supplements,
taking into consideration the effi-
cacy data and the fact that South
African doctors practise in a
resource-poor environment?
• How should the patient be deliv-
ered?
• Should the patient breast-feed
after delivery?
What is the evidence regarding
the use of ARVs in preventing
MTCT?
There is grade-A evidence from a
SR21 which compared  zidovudine
given antenatally, during labour
and after labour (for 6 weeks to the
baby and mother and with no
breast-feeding in the Connor et
al.22 trial), which found that
zidovudine decreased the incidence
of HIV in infants by 46% (RR
0.54, 95% CI 0.42 - 0.69).The
absolute risk reduction (ARR) was
11% which translates to a number
needed to treat (NNT) of 9 (95%
CI 7 - 14). In other words, using
this regimen one needs to treat on
average only 9 HIV-positive preg-
nant mothers to prevent 1 infant
from getting AIDS. Even when
shorter regimens were used several
RCTs22-24 showed that the NNT is
still low at 11.
Which regimen of ARVs should
be used?
When short-course (mother treated
from 35 weeks of pregnancy and
during labour and the infant given
treatment with zidovudine for up
to 3 days) zidovudine regimens
were compared with no treatment
or placebo, there was on average a
40% decrease in the incidence of
infant AIDS, with a NNT of 11.23,24
There is grade-A evidence from
RCTs27,28 which show that vitamin
supplements are no different from
no treatment or placebo for the
infant HIV incidence.
Should you use nevirapine or
zidovudine?
There is grade-B evidence from an
unblinded RCT21 that compared
intrapartum and neonatal single-
dose nevirapine (one dose to 
mother during labour and single
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In summary
• There is evidence from a SR
that shows that aciclovir does
not reduce the incidence of
CMV compared with placebo,
but significantly decreases HSV
and VZV and overall mortality.
• There is evidence from a RCT
that prophylaxis with valaci-
clovir reduces the incidence of
CMV when compared with aci-
clovir but is associated with an
increase in mortality in severely
compromised patients. (NB:
Use valaciclovir with caution in
patients with CD4 counts 
< 250 mm3.)
In summary
• There is grade-A evidence that
fluconazole given prophylacti-
cally once a week (400 mg) sig-
nificantly decreases the inci-
dence of candidal mucocuta-
neous infections.
dose to baby within 72 hours of
birth)  with zidovudine (given oral-
ly during labour and for 7 days to
the baby) for prevention of MTCT
of HIV-1 in Kampala. Single-dose
nevirapine was found to decrease
the incidence of HIV in the infants
at 14 - 16 weeks by 42% (RR 0.58,
95% CI 0.40 - 0.83) when com-
pared with those given zidovudine.
How should the patient be 
delivered?
There is grade-A evidence from a
SR21 that shows that elective cae-
sarean section (CS) at 38 weeks
decreases the number of infants
with HIV at 18 months by 84%
(RR 0.16, 95% CI 0.05 - 0.55;
NNT = 11) when compared with
spontaneous vaginal delivery.
However in our setting, where
operating theatre time and other
resources are limited and where
sepsis may be important, this
method of delivery should be indi-
vidualised to patients who have
access to full surgical delivery
options.
Should the patient breast-feed
after delivery?
There is grade-A evidence from a
RCT29 that compared the effect of
breast-feeding and formula feeding
on transmission of HIV-1 and
found that in mothers who breast-
feed their babies, there was a 100%
increase in the number of infants
with HIV at 24 months (RR 2.0,
95% CI 1.4 - 3.0). In other words,
for every 6 mothers who do not
breast-feed (and are provided with
clean water and formula feeds) 1
infant will avoid getting infected
with HIV. Again the implementa-
tion of this intervention must be
individualised and applied to
patients who have access to clean
water, formula feeds and health
education. If they do, this is a very
effective intervention.
References
1. Department of Health (2002). National HIV
and Syphilis Sero-prevalence Survey of
Women Attending Public Antenatal Clinics in
South Africa-2001, Summary Report.
http://www.doh.gov.za/docs/reports/2000/
hivreport/.html
2. Nelson Mandela/HSRC Study of HIV/AI DS,
South African National HIV Prevalence,
Behavioral Risks and Mass Media Household
Survey 2002.
http://www.hrscpublishers.co.za/hiv.html
3. Gallant JE, et al. Ann Intern Med 1994; 120:
932-944.
4. Wilkinson D. The Cochrane Library, Issue 4,
2002. Oxford: Update Software.
5. Bucher HC, et al. AIDS 1999; 13: 501-507.
6. Halsey NA, et al. Lancet 1998; 351: 786-
792.
7. Mwinga A, et al. AIDS 1998; 12: 2447-2457.
8. Whalen CC, et al. N Engl JMed 1997; 337:
801-808.
9. Gordin F, et al. JAMA 2000; 283: 1445-
1450.
10. Selwyn PA, et al. N Engl JMed 1989; 320:
545-550.
11. Bucher HC, et al. J Acquir Immune Defic
Syndr 1997; 15: 104-114.
12. Anglaret X, et al.Lancet 1999; 353: 1463-
1468.
13. El-Sadar W, et al. Clin Infect Dis 1999; 29:
775-783.
14. Schuman P, et al. Ann Intern Med 1997;
126: 689-696.
15. Powderly WG, et al. N Engl J Med 1995;
332: 700-705.
16. Havir DV, et al. Clin Infect Dis 1998; 27:
253-256.
17. Ioannidis JPA, et al. J Infect Dis 1998; 178:
349-359.
18. Feinburg JE, et al. J Infect Dis 1998; 177:
48-56.
19. Schacker T, et al. Ann Intern Med 1998;
128: 21-28.
20. Gallant JE, et al. Ann Intern Med 1994; 120:
932-944.
21. Brocklehurst P. The Cochrane Library, Issue
4, 2002. Oxford: Update Software.
22. Connor EM, et al. N Engl J Med 1994;
3111173-1180.
23. Shaffer N, et al. Lancet 1999; 353: 773-
780.
24. Wiktor SZ, et al. Lancet 1999; 353: 781-
785.
25. Shaffer N, et al. Lancet 1999; 353: 773-
780.
26. Fawzi WW, et al. J Acquir Immune Defic
Syndr 2000; 23: 246-254.
27. Coutsoudis A, et al. AIDS 1999; 13: 1517-
1524.
28. Guay LA, et al. Lancet 1999; 354: 795-
802.
29. Nduati R, et al. JAMA 2000; 283: 1167-
1174.
MAIN TOPIC
C M E S e p t e m b e r  2 0 0 3   Vo l . 2 1   N o . 9   515
In summary
• ARVs (zidovudine and nevi-
rapine) significantly decrease
MTCT of HIV.
• In our resource-poor environ-
ment, the single-dose nevirap-
ine regimen for mother and
baby is preferable to short
courses of zidovudine.
• For those patients who have
access to ARV, the earlier the
zidovudine is used (from 28
weeks of pregnancy and for 6
weeks in the infant), the lower
the risk of MTCT.
• Bottle feeding is a very effec-
tive way of preventing MTCT
as long as the mother has
access to clean water, formula
feed with heating facilities and
health education and care.
• Elective caesarean section is
an effective way of preventing
MTCT in a population that
has access to surgical
resources,ARVs before and
after delivery, formula feeds,
education and health support.
• Vitamin A or vitamin supple-
ments are no better than





patient represents a significant
percentage of patients seen in
general practice today in South
Africa.
It is important and beneficial to
know a patient’s HIV status in
order to prevent HIV-related mor-
bidity and mortality.
Anti-TB drugs given prophylacti-
cally to HIV-positive and tuber-
culin skin-positive patients reduce
their risk of active TB by as much
as 70% in the short term (2 - 3
years).
Trimethoprim/sulfamethoxazole
(TMP-SMX) — co-trimoxazole — is
more effective than pentamidine
or placebo and can reduce the
risk of PCP or toxoplasmosis in
patients who are HIV-positive by
as much as 60%.
Women taking weekly fluconazole
have a 58% decrease in the inci-
dence of candidiasis compared
with a 44% decrease in those
taking placebo.
